Redcare Pharmacy's 15 Million Customers Face Their First Real Test: Can Loyalty Pay?
Published on 11/11/2026 at 03:21 | Editorial boerse-global.de
Redcare Pharmacy has crossed a threshold that most European e-commerce businesses can only dream of: more than 15 million active customers across seven markets. The shares rose 2.1% on Thursday as the figure sank in. But the number itself is not the story. What matters now is whether that customer base can be converted into durable profit — and on that front, the evidence is mixed.
The company's third-quarter results, published roughly two weeks ago, offer both encouragement and a warning. Revenue climbed 18% to EUR 847 million, powered by prescription medicines. Adjusted EBITDA reached EUR 28.7 million, translating into a margin of 3.4% — an improvement of 1.0 percentage point year on year. Growth and profitability arrived together, which is precisely the combination investors want to see sustained.
Repeat Orders Are Only Half the Argument
Management reports that the reorder rate in the third quarter of 2026 exceeded 90%. That figure, paired with the 15 million customer milestone, suggests a loyal base that keeps coming back. Yet loyalty alone does not pay the bills. The economic value of repeat business depends on whether those orders carry enough margin to justify the volume.
This is where the investment case becomes a balancing act. A high reorder rate strengthens the bull case only if it translates into a reliable earnings contribution. Expanding reach without improving profitability would be the weaker argument. The quality of growth, not its scale, sits at the center of the debate.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
October Brings a Sobering Data Point
The optimism has a counterweight. According to media reports, management said on the earnings call that growth in non-prescription products started October at less than 10%. The cold-and-flu season got off to a slow start. The company also pointed to intense competition and expected growth in prescription medicines to weaken against a strong prior-year comparison.
That slower start matters because it shows how much the growth narrative depends on day-to-day trading, not just on the size of the customer base. Redcare still expects 10%–12% growth in over-the-counter products for the full year, and its German prescription business is guided to EUR 730 million–760 million in revenue. Group revenue is forecast to grow 16%–18% in 2026 — a target confirmed roughly two weeks ago and one that would extend the momentum of the latest quarter.
Analysts See Higher Operating Profit but Lower Earnings per Share
A mixed signal arrived about a week ago from MPCM. The research house raised its EBIT estimates for 2026–2028 but simultaneously cut its earnings-per-share expectations, according to media reports. It lifted its price target to EUR 125 and kept its buy rating.
That combination — more operating profit, less profit per share — is a useful reminder that the bottom line investors actually receive can diverge from headline operating progress. A convincing story would need to bring both levels closer together.
Redcare Pharmacy at a turning point? This analysis reveals what investors need to know now.
London and Paris Provide the Next Stage
Redcare has announced it will appear at the Jefferies Healthcare Conference in London on November 18, 2026, and at the Bank of America Consumer Conference in Paris on November 19, 2026. Those appearances will give management a fresh audience and a fresh set of questions.
The next concrete checkpoint, though, is execution against the confirmed full-year guidance. Broad-based progress across business segments would be more persuasive than growth concentrated in one part of the plan. If Redcare hits its revenue corridors while holding or improving operating profitability, the customer-loyalty story gains real weight. If margins come under pressure instead, the 15 million customers will look less like a foundation and more like an unfinished promise.
Ad
Redcare Pharmacy Stock: New Analysis - 11 November
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
